Drug Type Small molecule drug |
Synonyms CT-707, SY-707, 首要泽 |
Mechanism ALK inhibitors(Anaplastic lymphoma kinase inhibitors), FAK inhibitors(Focal adhesion kinase inhibitors), IGF-1R antagonists(Insulin-like growth factor I receptor antagonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Molecular FormulaC32H45N9O3S |
InChIKeyNPJCURIANJMFEO-UHFFFAOYSA-N |
CAS Registry1384860-29-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
ALK positive Non-Small Cell Lung Cancer | NDA/BLA | CN | 23 Oct 2024 | |
ALK positive Non-Small Cell Lung Cancer | NDA/BLA | CN | 23 Oct 2024 | |
Pancreatic Cancer | Phase 2 | CN | 19 Oct 2022 | |
Advanced Pancreatic Adenocarcinoma | Phase 2 | CN | 11 Aug 2022 | |
Non-Small Cell Lung Cancer | Phase 1 | CN | 21 Oct 2020 | |
Hepatocellular Carcinoma | Preclinical | CN | 01 Dec 2016 | |
Hepatocellular Carcinoma | Preclinical | CN | 01 Dec 2016 |
NCT02695550 (Pubmed) Manual | Phase 1 | 60 | (ALK TKI-naïve) | dgysrlijty(ifwdggnneo) = MTD was not reached pgzeahyvmn (eofdpbbbyu ) View more | Positive | 23 Nov 2022 | |
(received crizotinib previously) | |||||||
Phase 1 | 13 | fvqzvsxveq(yotbotigoj) = diarrhea 92%, elevated aspartate aminotransferase 61%, elevated alanine aminotransferase 54%, hair loss 38%, vomiting 31% katkaqrndh (ctzylolbsb ) View more | Positive | 23 Nov 2019 | |||
Phase 1 | ALK positive Non-Small Cell Lung Cancer ALK Positive | 23 | toamtncljr(izafbhhnfu) = none fiqrxfpjww (wvvbcvkktl ) View more | Positive | 18 Nov 2017 |